On March 3, 2026, Citi Pharma Limited announced the initiation of an initial public offering (IPO) for its wholly owned subsidiary, Citi Veterinary Pharma Limited, with plans to raise between Rs1 billion and Rs2 billion. The Board of Directors has appointed K-Trade Securities Limited as the consultant to manage the IPO process. This strategic move aims to diversify Citi Pharma's revenue sources within the pharmaceutical sector, particularly focusing on veterinary products, which are expected to generate approximately Rs1.5 billion in revenue in FY26.
BUSINESSLast Update 15h ago
Citi Pharma Plans Rs1-2 Billion IPO for Vet Subsidiary
100% NEUTRAL
Citi Pharma Limited has approved an IPO for its subsidiary, Citi Veterinary Pharma Limited, aiming to raise Rs1-2 billion. This move is part of a strategy to diversify revenue streams, with projected revenues of Rs1.5 billion from veterinary products in FY26.
Detailed Analysis
SOURCES
4 outlets · 4 articles
PPprofit.pakistantoday.com.pk
PRpropakistani.pk
BRbrecorder.com
MAmarketscreener.com